Many in vitro and in vivo data are available supporting the role of mesenchymal stromal cell (MSC) licensing in the induction of a measurable and effective immune regulation. The failure of some MSC-based protocols for immune modulation in animal models and in human clinical trials may be explained by either lack of a proper licensing by inflammatory microenviroment or wrong timing in MSC administration. Thus, optimization of MSC use for immune-regulating purposes is required to maximize their beneficial effects.

Mesenchymal stromal cell ‘licensing’: a multistep process

KRAMPERA, Mauro
2011-01-01

Abstract

Many in vitro and in vivo data are available supporting the role of mesenchymal stromal cell (MSC) licensing in the induction of a measurable and effective immune regulation. The failure of some MSC-based protocols for immune modulation in animal models and in human clinical trials may be explained by either lack of a proper licensing by inflammatory microenviroment or wrong timing in MSC administration. Thus, optimization of MSC use for immune-regulating purposes is required to maximize their beneficial effects.
2011
Mesenchymal stromal cell; immunological licensing
File in questo prodotto:
File Dimensione Formato  
Krampera MSC licensing Leukemia 2011.pdf

solo utenti autorizzati

Tipologia: Documento in Post-print
Licenza: Accesso ristretto
Dimensione 332.89 kB
Formato Adobe PDF
332.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11562/360416
Citazioni
  • ???jsp.display-item.citation.pmc??? 168
  • Scopus 275
  • ???jsp.display-item.citation.isi??? 280
social impact